A Multicenter, Open Label Single Arm Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in HER2 Overexpressing Local Advanced or Metastatic Gastric Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs RC 48 (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Sponsors RemeGen
- 18 Jul 2019 Planned End Date changed from 31 Dec 2019 to 31 Aug 2020.
- 18 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2020.
- 21 Jun 2018 New trial record